Standard Chartered Expands Hedge Fund Access for Wealth Clients 
Alphabet Eyes First Australian Dollar Bond as AI Spending Drives Funding Push 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3 
Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits 
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
REPAY Stock Rises After Visa Platform Connect Collaboration 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case 
Hermès Stock Downgraded by RBC as Luxury Growth Premium Narrows 
Alibaba Sells Lingxi Games for Over $1.5 Billion Amid AI Push 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO 
Add as a preferred source on Google
Bristol Myers Squibb Co would buy MyoKardia Inc for about $13 billion to bolster its portfolio of heart disease treatments and shield itself from competition posed by Merck & Co’s Keytruda on its for its cancer immunotherapy, Opdivo.
The deal gives Bristol Myers, which acquired pharmaceutical company Celgene last year for $74 billion, access to Myokardia’s lead heart drug candidate with blockbuster potential, mavacamten.
According to David Nierengarten, a Wedbush analyst, mavacamten is expected to be a “multi-billion dollar asset” as sales estimates for the treatment of obstructive hypertrophic cardiomyopathy (HCM) is expected to reach about $2.5 billion by 2026.
Hypertrophic cardiomyopathy is estimated to affect one in every 500 people globally.
MyoKardia expects to submit a marketing application to the US health regulator for mavacamten as an obstructive HCM treatment in the first quarter of 2021.
Bristol Myers' portfolio of heart drugs includes blood thinner Eliquis, which made up about 21 percent of the company’s total sales in its latest reported quarter.
